Project ID：DT-20250428-041
Product Brief Summary
- Product Name: A once daily oral brain-penetrant dual JAK1/TYK2 inhibitor with better efficacy and safety
- Modality: Small Molecule
- Target: JAK1/TYK2
- Therapeutic Area: Neuroinflammatory diseases, such AD, PD, MS and others; Non-CNS autoimmune diseases, such SLE, CD and others
- Current Stage: IND-enabling, to be filed in Q4 2025
- Rights Available: Global Right
- Collaboration Mode: License out / co-development
More highlights
- JAK1/TYK2i activity: the candidate is more potent than BHV-8000 (12X) and Upadacitinib (3X) in cellular assay
- Desirable Selectivity: > 40 folds JAK1 over JAK2
- Candidate shows favorable brain penetration and longer lasting brain exposure than BHV-8000
- Ameliorates the symptoms and neuroinflammation in both rat & mouse models of Parkinson’s disease (PD) at lower dose than BHV-8000
- Non-GLP toxicity studies almost completed
Contact us:
For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 